Skyrizi Subcutaneous (risankizumab-rzaa) — Cigna

Crohn’s disease

Initial criteria

age > 18 years
According to the prescriber, patient will receive induction dosing with Skyrizi intravenous within 3 months of initiating therapy with Skyrizi subcutaneous
Patient meets ONE of the following: has tried or is currently taking corticosteroids, or corticosteroids are contraindicated; OR has tried one other conventional systemic therapy for Crohn’s disease (e.g., azathioprine, 6-mercaptopurine, methotrexate); OR patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas; OR patient had ileocolonic resection
Medication is prescribed by or in consultation with a gastroenterologist

Patient has been established on therapy for at least 6 months
Patient meets at least ONE of the following: when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline; OR compared with baseline, patient experienced improvement in at least one symptom such as decreased pain, fatigue, stool frequency, and/or blood in stool

initial 6 months; reauth 1 year